This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

The present invention relates to neutralizing monoclonal antibodies or antigen-binding fragments thereof that are specific for and bind with high affinity to Varicella-Zoster Virus, and a preparation method for producing such antibodies. The antibodies of the present invention have high efficiency in neutralizing Varicella-Zoster Virus infection. The present invention also relates to the epitope to which the antibodies bind and the use of the antibodies in the diagnosis, prevention and treatment of infected individuals.

Monoclonal antibodies and antigen binding fragments that specifically bind to the Human Cytomegalovirus (HCMV) pentamer protein complex (gH/gL/UL128/UL130/UL131A) or other gH-containing complexes, and uses thereof.

Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

The disclosure relates to the use of a combination of antibodies or antigen binding fragments thereof to hCMV; and to dosages, ratios and minimum trough serum concentrations of the antibodies. The combination is useful for the neutralization of hCMV, for example, in pregnant, immunocompromised or immunosuppressed patients undergoing bone marrow and organ transplants with a low occurrence of viral resistance.

A T cell antigen receptor, an immune cell for expressing the T cell antigen receptor (TCR) and a preparation method and use thereof. The TCR disclosed in the present invention can be specifically activated by virus antigen peptide presenting cells, so that the release level of extracellular cytokines IFNγ and IL2 and the release amount of lactate dehydrogenase are improved, and target cells are significantly killed.

Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

The present disclosure relates to anti-human cytomegalovirus (anti-HCMV) antibodies and vaccines as well as diagnostic and therapeutic methods of use.